Company profile
Medline Inc.
NASDAQ:MDLNMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Chlorhexidine Gluconate | approved | — | 7 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02530541 | phase1_2 | completed | 2014-04-01 | 2014-07-01 | Medline Industries | Antimicrobial Efficacy of 2% CHG (Chlorhexidine Gluconate) |
| NCT03326726 | phase2 | completed | 2016-11-16 | 2016-11-18 | Medline Industries | Evaluation 2% Chlorhexidine Gluconate |
| NCT02224625 | phase3 | completed | 2014-08-01 | 2015-06-01 | Medline Industries | Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth |
| NCT02530554 | phase1_2 | completed | 2015-07-01 | 2015-08-01 | Medline Industries | Pilot Trial of Chlorhexidine Gluconate (CHG) Preoperative Skin Preparation |
| NCT02530528 | phase1_2 | completed | 2014-02-01 | 2014-04-01 | Medline Industries | Pilot Trial of Preoperative Chlorhexidine Gluconate (CHG) Skin Preparation |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 207964 | NDA | MEDLINE INDUSTRIES INC | ||||
Loading… | ||||||